Category Archives: Epigenetics

An analysis report published by DataIntelo is an in-depth study and detailed information regarding the market size, market performance and market dynamics of the Epigenetics. The report offers a robust assessment of the Epigenetics Market to understand the current trend of the market and deduces the expected market trend for the Epigenetics market for the forecast period. Providing a concrete assessment of the potential impact of the ongoing COVID-19 in the next coming years, the report covers key strategies and plans prepared by the major players to ensure their presence intact in the global competition. With the availability of this comprehensive report, the clients can easily make an informed decision about their business investments in the market.

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=84512

This detailed report also highlights key insights on the factors that drive the growth of the market as well key challenges that are expected to hamper the market growth in the forecast period. Keeping a view to provide a holistic market view, the report describes the market components such as product types and end users in details with explaining which component is expected to expand significantly and which region is emerging as the key potential destination of the Epigenetics market. Moreover, it provides a critical assessment of the emerging competitive landscape of the manufacturers as the demand for the Epigenetics is projected to increase substantially across the different regions.

The report, published by DataIntelo, is the most reliable information because it consists of a concrete research methodology focusing on primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives and representatives and accessing official documents, websites, and press release of the companies. The DataIntelos report is widely known for its accuracy and factual figures as it consists of a concise graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years.

Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the Epigenetics market are thoroughly assessed in the report in a view to entail a broader picture of the market.

Key companies that are covered in this report:

IlluminaThermo Fisher ScientificMerck MilliporeAbcamActive MotifBio-RadNew England BiolabsAgilentQiagenZymo ResearchPerkinelmerDiagenode

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application and regions. Moreover, the report also takes into account the governments policies in the evaluation of the market behavior to illustrate the potential opportunities and challenges of the market in each region. The report also covers the recent agreements including merger and acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Epigenetics market.

By Application:

OncologyMetabolic DiseasesDevelopmental BiologyImmunologyCardiovascular DiseasesOther Applications

By Type:

DNA MethylationHistone ModificationsOther Technologies

You can also go for a yearly subscription of all the updates on Epigenetics market.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=84512

According to the report, the Epigenetics market is projected to reach a value of USDXX by the end of 2027 and grow at a CAGR of XX% through the forecast period (2020-2027). The report covers the performance of the Epigenetics in regions, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing some key countries in the respective regions. As per the clients requirements, this report can be customized and available in a separate report for the specific region and countries.

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Epigenetics Market Overview

Epigenetics Supply Chain Analysis

Epigenetics Pricing Analysis

Global Epigenetics Market Analysis and Forecast by Type

Global Epigenetics Market Analysis and Forecast by Application

Global Epigenetics Market Analysis and Forecast by Sales Channel

Global Epigenetics Market Analysis and Forecast by Region

North America Epigenetics Market Analysis and Forecast

Latin America Epigenetics Market Analysis and Forecast

Europe Epigenetics Market Analysis and Forecast

Asia Pacific Epigenetics Market Analysis and Forecast

Middle East & Africa Epigenetics Market Analysis and Forecast

Competition Landscape

Why you should buy this report?

The report also answers some of the key questions given below:

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=84512

About DataIntelo:

We keep our priority to fulfil the needs of our customers by offering authentic and inclusive reports for the global market-related domains. With a genuine effort from a dedicated team of business experts, DataIntelo has been in the service by providing innovative business ideas and strategies for the current global market for various industries and set its benchmark in the market research industry.

We have a large support of database from various leading organizations and business executives across the globe; so, we excel at customized report as per the clients requirements and updating market research report on the daily basis with quality information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read more:
Global Epigenetics Market by Trends, Dynamic Innovation in Technology and Key Players| Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam,...

The Fountain of Youth -- an enduring aspiration, particularly as the ravages of age reduce human faculties prior to leading inexorably to death. Reduction in sight is the human faculty that can have the greatest effect on quality of life in the aged -- a faculty that begins to decline in the 4th or 5th decade of life and doesn't get better (when it does) without medical intervention.

But what if there were a way to rejuvenate sight? That prospect is the tantalizing suggestion in a paper published on December 2nd entitled "Reprogramming to recover youthful epigenetic information and restore vision," Nature 588: 124-29*. The basis of the report is the recognition that many of the age-related effects on vision are an example of gene expression differences associated with epigenetic changes in chromosomal DNA. Epigenetics is a phenomenon of gene structure and expression involving small differences in nucleotide bases, typically methylation of cytosine residues at specific (CpG) sites. These changes have been studied in normal development, where gene expression changes arise as different cell types properly differentiate and act as a molecular "clock" reflecting age. The ability to turn back cellular time has been demonstrated by the development of induced pluripotent stem cells (iPSCs), wherein terminally differentiated somatic cells (typically fibroblasts) can be turned into pluripotent cells. Pluripotent cells are capable of differentiating into cells of each embryonic germinal layer (ectoderm, mesoderm, endoderm), and iPSCs can be produced by expressing four specific genes: OCT4, SOX2, KLF4 and MYC. All of these genes encode transcription factors capable of affecting (and effecting) developmentally relevant gene expression. Consequent to this "de-differentiation" occasioned by expression of these genes is a "resetting" of the epigenetic patterns associated with development. In this paper the researchers hypothesized that resetting these epigenetic patterns could also rejuvenate neuroretinal cells to reinvigorate and overcome the ocular nerve damages by glaucoma in an animal model.

Because one of these genes (MYC) is also associated with cancer development (i.e., it is an oncogene) the researchers developed an inducible expression construct that expressed only the OCT4, SOX2, and KLF4 members of the quartet (OSK). (This decision was also informed by the experience of other researchers that continuous expression of all four genes in animal models resulted in teratomas or was fatal within days of introduction.) Their system used a polycistronic (i.e., all the genes in one linear array) construct of all three genes regulated by a tetracycline response element (TRE) promoter in a adeno-associated viral vector. This construct was tested by introduction into fibroblasts from aged (20 month old) mice and gene expression related to aging (i.e., that showed differential expression with age) was evaluated. These studies showed that OSK expression for 5 days resulted in a "youthful" mRNA expression pattern in these genes (without any effect on the terminal differentiation state of the fibroblasts).

The TRE promoter enabled selection for or against expression of the OSK gene cassette; as the authors explain "[t]he TRE promoter can be activated either by reverse tetracycline-controlled transactivator (rtTA) in the presence of the tetracycline derivative doxycycline (DOX) ('Tet-On') or by tetracycline-controlled transactivator (tTA) in the absence of DOX ('Tet-Off')." Simply put, the presence of absence of DOX in the animal's drinking water determined whether the expression cassette is "on" or "off," as illustrated in this figure:

Long-term (10-18 months) expression of this cassette was achieved in both young (5 months-old) and aged mice with no tumorigenesis or other negative side effects being observed.

To test the ability of induced OSK expression to rejuvenate optical nerve cells the researchers examined retinal ganglion cells (RGC, which project axons away from the retina informing the optic nerve) in an optic nerve crush injury model (which mimics the effects of optic nerve injury due to inter alia glaucoma). The construct was delivered by injection into the vitreous humor and resulted in about 37% of the RGCs taking up and expressing the OSK genes in response to DOX administration. A separate cohort of mice were administered versions of the construct where DOX inhibited OSK expression. In these experiments, "the greatest extent of axon regeneration and RGC survival occurred when all three genes were delivered and expressed as a polycistron within the same AAV particle" according to the researchers. In contrast, inhibition of OSK expression in the "Tet-Off" mice showed no axonal growth. Moreover, delivery of the OSK genes individually in separate viral vectors or in pairs also did not show axonal growth, indicating the need for these genes to be expressed together in proper relative amounts provided by the polycistronic construct. The researchers also found OSK expression induced expression of Stat3, a gene know to encourage regeneration. These results were obtained in using 12-month-old mice as well as 1- and 3-month-old mice, which indicated, as the authors note, that "ageing does not greatly diminish the ability of OSK transcription factors to induce axon regeneration." Increased axonal growth from RGCs was found even after crush injury, an effect found with no other treatment modalities.

The researchers then determined whether these reinvigorated RGCs showed changes in DNA methylation patterns. In the absence of DOX-induced OSK expression injury in this model caused an "accelerated" aging pattern, whereas in the presence of DOX-induced OSK expression counteracted this effect according to the results reported in this paper. Interestingly, this preservation of a "youthful" pattern of DNA methylation was found to be enriched at genes "associated with light detection and synaptic transmission." Having shown this association the researchers then investigated whether axonal regeneration required youthful changes in DNA methylation. These experiments were performed by reducing expression of genes that caused DNA demethylation in RGCs (and whose expression was known to be increased in cells expressing OSK) and detecting that axonal regeneration did not occur in these mice even in the presence of DOX-induced OSK expression.

Whether these effects of OSK expression would also be seen in human neurons was investigated using differentiated human neurons in vitro. Neurons harboring an OSK-encoding construct were treated with vincristine (a drug that occasions axon injury) and DOX-induced OSK expression was shown to "counteract[] axonal loss and the advancement of DNA methylation age," showing a 15-fold greater area of proliferation in OSK-expressing cells than control vincristine-treated neural cells. These cells also showed the demethylation-dependent characteristics that were shown in RGCs in the mouse optic nerve crush injury model.

The most clinically significant result disclosed in this paper involved the effect of OSK expression in a glaucoma model in vivo. Intraocular pressure was increased to pathological levels by injecting microbeads unilaterally into the anterior chamber of mouse eye for 21 days. At 4 weeks, after these animals showed correspondingly unilateral decreases in axonal density and the number of RGCs present in the treated eye. The viral vector encoding inducible OSK expression thereafter was introduced by intravitreal injection followed by DOX-induced OSK expression for 4 weeks. Compared with control (introduction of saline or viral vectors not encoding OSK into the microbead-treated eyes) the OSK vector-treated eyes showed "restored axon density equivalent to that in the non-glaucomatous eyes, with no evidence of RGC proliferation." These mice also showed a reversal of vision loss caused by the glaucomatous injury. Together these results indicated that OSK expression could be a therapy for glaucoma in humans.

Finally, the paper reports efforts to determine whether OSK expression could improve age-related (as opposed to injury- or pathology-related) vision problems. In these experiments, 3-and 11-month-old mice were treated by intravitreal injection of DOX-inducible OSK encoding constructs and OSK expression induced for 4 weeks. Twelve-month-old mice showed age-related visual acuity and RGS electrical activity diminution which was reversed by DOX-induced OSK expression. However, these phenotypic changes were not observed to be associated with an increased number of RGCs or axon density, which prompted these researchers to hypothesize that the effect were dependent on changes in gene expression ("transcriptomic changes" as these were termed in the paper). RGCs from treated or untreated 12-month-old mice were isolated and compared with RGCs from 5-month-old mice and expression of 464 genes were found to be altered: expression of almost all (90%) of these genes were found to be restored to youthful levels in OSK-expressing RGCs. The participation of DNA methylation changes in aged RGCs in producing a youthful pattern of gene expression was further assessed and validated using artificial intelligence/machine learning approaches.

The results reported in this paper suggest therapeutic interventions that could improve vision in the aged human population even in the absence of vision-impairing pathologies such as glaucoma. Although cautious to mention that "we do not wish to imply that DNA methylation is the only epigenetic mark involved in this process" and "[i]t is likely to involve other transcription factors and epigenetic modifications," the authors are not blind to the implication that:

[W]e show that it is possible to safely reverse the age of a complex tissue and restore its biological function in vivo. Using the eye as a model system, we present evidence that the ectopic expression of OSK transcription factors safely induces in vivo epigenetic restoration of aged CNS neurons, without causing a loss of cell identity or pluripotency. Instead, OSK promotes a youthful epigenetic signature and gene-expression pattern that causes the neurons to function as though they were young again. The requirement for active demethylation in this process supports the idea that changes in DNA methylation patterns are involved in the ageing process and its functional reversal.

* By researchers from Harvard Medical School, Yale University School of Medicine, Massachusetts General Hospital, UCLA Geffen School of Medicine, and The University of New South Wales Medical School.

Excerpt from:
Epigenetic Changes Implicated in Age-related Diminution in Vision and Its Possible Reversal - JD Supra

Drought costs farmers around the world 10bn in crop losses every year but new trial results show that combining biostimulants with micronutrients could be the answer to food security.

The study, by researchers at Nottingham Trent University in collaboration with Micromix, looked at the effect of a hybrid biostimulant with nutrients on drought and heat tolerance in a range of crops. It found that the product changed the plants response to stress, increasing drought tolerance by 25-35% and boosting yields by up to 30%.

This is really game-changing it could offer a big contribution to global food security, says Chungui Lu, Professor of sustainable agriculture at the University. In the UK alone, we could save millions of Pounds in lost crops.

Abiotic stress - due to extreme temperatures, water, salt and solar radiation - induce a metabolic and epigenetic change in a plant, weakening its natural defense mechanisms and increasing its susceptibility to disease, pests and subsequent crop failure, explains Prof Lu. Biostimulants have the potential to affect a plants response to this stress, stimulating its own natural processes, while micronutrients enrich its growing environment. This new formulation comprises a number of key nutritional materials, including micronutrients, in a novel combination with several biostimulant components, which will suppress abiotic stress and stimulate further growth.

The trial is the latest to be carried out on this new technology, after it produced remarkable effects under initial testing on protected salad and field crops in the Middle East, South East Asia and Europe. We realised we had accidentally discovered a new kind of synergy, and needed to validate it scientifically, says Wilson Boardman, founder at Micromix and product developer. In 2014, with Prof Lu, he secured a 247,000 Innovate UK research grant, through which they discovered that the key genes relating to heat tolerance were strongly upregulated by the new technology.

This 2014 trial focused on bell peppers, which are very heat sensitive at 28C they start to wilt and at 30C they stop growing. But the treated crops were still actively growing at over 30C, boosting yields by 20% and shelf life by 44%, alongside an improvement in fruit mineral content. This has directly led to important new discoveries in epigenetics and a further research project, says Prof Lu.

In 2018 Mr Boardman and Prof Lu secured an 807,948 Innovate UK grant to further investigate the genetic influence of the product. Prof Lu looked at a variety of crops, including wheat, peas, Pak choi and potatoes, and discovered specific genes which were triggered by the biostimulants, using plant genomic / transcriptomic technologies. This reduced the negative impact of stress and stimulated plant growth.

We identified 178 key genes that are affected by the new biostimulant technology, which provides insight into gene regulation and molecular markers for breeding programmes targeted at drought tolerance, says Prof Lu. This will have a big impact for agriculture, protecting against climate change and directly protecting crop growth and quality. For example, treated crops increased cutin formation and reduced respiration, preventing water loss, while also increasing some enzymes and defense activity, boosting nutrient transfer, growth and disease resistance.

Prof Lu plans to publish his scientific paper in early 2021, and will then apply for further grant funding to help develop the next generation of biostimulants. We want to design larger field trials across more crops, to identify the correct rate and timing of application for different crops.

Micromix plans to launch products based on the research to market in the next two years, although application techniques will be refined as the research continues. The University is really excited, says Prof Lu. It will be really good to do further research into improved crop quality. The outputs of the research will enable the successful commercialisation of novel farming systems, which will in turn help to improve food security, reduce the environmental impact of food production, create local employment and contribute to community health, wellbeing and sustainability.

For more information:Micromixwww.micromix.com

Read more:
Biostimulants fighting drought and heath - hortidaily.com

Some of the below was reprinted with permission from World at Large, a news outlet focusing on space, health, conservation, environmental and foreign policy, and travel.

Researchers at Harvard Medical School have successfully restored vision loss and reversed glaucoma-induced damage in mice.

In the mice, the retinal ganglion cells, a principal cell that enables vision, were restored to a youthful state in cases of glaucoma, as well as when the optic nerve, another key component of eyesight, had been damaged. Both were achieved through expressing certain transcription factorsproteins that turn genes on and off.

The study sheds light on the mechanisms of ageing, and identifies new potential therapeutic targets for age-related neuronal diseases such as glaucoma, reads a statement from researchers at Harvard Medical School.

The new study, published in Nature, was conducted by Dr. David Sinclair, of the worlds foremost experts on ageing-related research in mice.

Along with genetic research, Sinclair has also looked at how supplement-ready compounds like resveratrol and Metformin affect aging, and his book, Lifespan: Why We Age and Why We Dont Have To, is a New York Times bestseller.

The science behind Sinclairsnew paper involves the curious process of methylation. Governed by epigeneticsthat is, changes in the genetic expression of the cell over timethe researchers found that methylation in mammalian tissues prevents the cells from replicating proteins properly while simultaneously encoding a kind of genetic history.

RELATED: 8-Year-old Sees Stars for the First Time After His Blindness is Treated With Gene Therapy

One can imagine this as scratches on the bottom of a CD. If the scratches could be removed, the record of proper function is still there, and could still be read by the laser in a CD player.

In his book, Sinclair details the modern theory of aging, which is that changes in epigenetics and damage to cells and tissues prevent the body from properly reading protein-encoding genes, resulting in either faulty, less-functional, i.e. older genes being transcribed, or the proteins not being replaced at all.

Here the authors found that when the mouse neurons were recovering from damage related to glaucoma, the methyl groups which built up over time left, like the scratches being removed from a disk.

This resulted in a process called demethylation. Demethylation was associated with younger genetic expression, in other words, the mouses genes remembered how to be young again, only after demethylation had occurred.

READ: First-of-Its-Kind Study Finds Shining a Red Light Through the Eyelid for 3 Minutes Per Day Can Boost Failing Eyesight

These data indicate that mammalian tissues retain a record of youthful epigenetic informationencoded in part by DNA methylationthat can be accessed to improve tissue function and promote regeneration in vivo, write the authors in their summary.

It remains to be seen whether records of youthful genetic expression are contained within other mammalian tissues, the liver for a random example, through methylation, and whether or not they can be accessed through demethylation.

MORE: Breakthrough App Guides Blind Runner on Solo 5k Run Through Central Park

If its true that simply altering some transcription factors is enough to clear the dust off the rule book for how to build young proteins, Sinclair stands to make a major breakthrough.

SHARE the News of This Exciting ResearchWith Friends

More here:
Blind Mice with Glaucoma See Again Through Simple Technique that Promotes Youthful Gene Expression - Good News Network

FERNANDINA BEACH, Fla., Dec. 9, 2020 /PRNewswire/ -- Ponce De Leon Health, Inc. ("Ponce de Leon"), a longevity research company focused on the reversal of epigenetic aging, announced today that Brian Kennedy, Ph.D., will speak at the SupplySide Network "Healthy Aging Never Gets Old" event on December 10th, 2020, at 1:00 PM Eastern.Doctor Kennedy is currently serving as Director of the Centre for Healthy Longevity, at the National University of Singapore.Registration for this free event can be found on theSupplySide Network 365platform.

Doctor Kennedy was invited to address industry leaders to discuss recent research which led to the development of Rejuvant LifeTabs, a dietary supplement designed for healthier aging. Informa Health & Nutrition named Rejuvant LifeTabs asthe top Consumer Packaged Goods winner in the Best Life-Span Specificcategory, at the 2020 NEXTY SupplySide Awards. According to Informa, Rejuvant contains "a ground-breaking ingredientLifeAKGand a meticulously researched, time-release formula tailored to men and women."

This news follows on the heels of Ponce De Leon Health announcement in September with the first peer-reviewed study of a non-drug substance demonstrating improvements in mammalian lifespan, reduction in frailty, and reduction in time of suffering. The results of the research were published in the September 1, 2020 issue of the journal Cell Metabolism. The researchers found that LifeAKG "promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines. Strikingly, the reduction in frailty led the scientists to "propose that Ca-AKG compresses the period of morbidity." The publication, titled "Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice," and was authored by Azar Shamirzadi, Ph.D., et al., and directly led to the development of Rejuvant LifeTabs.

Tom Weldon, the CEO and Founder of Ponce De Leon Health, remarked, "We're very proud of our research, past and ongoing, and committed to reversing epigenetic aging. Our product, Rejuvant LifeTabs, is emblematic of the growing discoveries in the field of epigenetics, or the changes made by modification of gene expression.We continue to conduct new human and animal trials to better demonstrate the benefits of Rejuvant on biological aging, healthspan and lifespan."

Todd Runestad, Senior Editor of Ingredients and Supplements, New Hope Media and Natural Products Insider, invited Dr. Kennedy to speak at the event.Said Mr. Runestad, "healthy aging is a prime consideration of supplement usersfrom specific health conditions like bone or joint or cognitive health, to the more general concept of aging gracefully. Of course, people have long sought out skin-health products, but the new frontier is the provocative research around epigenetics and nutrigenomicsthat one's lifespan is not just predicated on genetics, but that gene expression can be modulated by diet and specific dietary supplements."

Mr. Runestad added, "Brian Kennedy has been researching such concepts for decades now. He is one of the world's leading anti-aging researchers, and he may have come up with this decade's resveratrolthe fountain of youth molecule found in red wine. We awarded a NEXTY award for the year's best innovation, integrity and inspiration, to a supplement brand Dr. Kennedy helped develop for Ponce de Leon Health. The company's Rejuvant LifeTabs, coupled with an in-home genetic test kit, allows consumers the ability to actually track over time genetic markers of aging while taking the supplement. Personalized health care meets anti-aging science."

About Ponce De Leon HealthPonce De Leon Health (www.PDLHealth.com) is a commercial-stage longevity company focused on the discovery, development and commercialization of non-prescription consumer products to address the reversal of epigenetic aging. Their goal is to increase human healthspan, improve quality of life, and reduce the cost of providing late stage health care to customers.

To learn more about the groundbreaking science behind Rejuvant LifeTabsvisit http://www.rejuvant.com or follow @rejuvanthealth(Facebook), @Rejuvant (Twitter), or Ponce De Leon Health (YouTube).

SOURCE Ponce De Leon Health

http://pdlhealth.com

See more here:
Leading Healthy Aging Researcher Brian Kennedy, Ph.D., To Address Natural Health Industry On Impact Of Nutrition On Biological Age - PRNewswire

Scientists have known since ancient times, as notable in Greek mythology, that liver tissue has a remarkable ability to regenerate, but embryologist Kim Tremblay, veterinary and animal sciences, says, We still dont know how it does that, its still a mystery even after two thousand years.

She now has a five-year, $1.4 million grant from the NIHs National Institute of Diabetes and Digestive and Kidney Diseases to investigate how the organ can replace itself in an amazingly short time. Unlike any of our other organs, if you cut out two-thirds of your liver, it will grow back in seven days, she says. Whats amazing about that time is that in many organisms that have a liver, it can grow back in seven days.

The liver filters impurities, toxins, alcohol and drugs, for example, from the bloodstream, which kills many cells, so in a sense its not surprising that the organ can quickly respond to injury by making new ones, Tremblay says. There is a reservoir of cells that replace the dead ones. The liver has a huge number of regenerative or homeostatic cues that trigger this, but we have not yet established which cells are responsible for this.

As a developmental biologist, Tremblay will focus on how hepatic cell types emerge during embryonic development. Using this strategy, she hopes to address long-standing disagreement in the field regarding the cells that are involved in regeneration. Some scientists think its one type, others insist it is another, she says, but the problem is that they are often using different regeneration models. What if adult cells are able to respond to distinct regenerative cues in unique ways because of where or how they arose in the embryo?

In the embryonic liver bud, she explains, embryonic precursor cells called hepatoblasts differentiate into two distinct adult cell types hepatocytes and cholangiocytes. Researchers have varying views about which of these might hold the regeneration key. We do know they arise in different developmental pathways in the embryo and they look different in an adult, Tremblay adds.

Her previous experiments in a culture system she developed show that hepatoblasts, the hepatic precursor cells, respond differentlyto cues growth factors and other signals in the embryo. Tremblay believes that a new series of investigations in a mouse liver model using targeted genetic techniques will show that both cell types harbor more than one as-yet-undiscovered variant.

I think we havent yet discovered the differences within those groups, the embryologist says. The grant is designed to explore this heterogeneity in development. Well use RNA transcript analysis from knock-out mice to identify the roles of particular genes, and well also explore ATAC-Seq. ATAC-Seq is a sensitive technique used to look for epigenetic memory, which is where Tremblay hypothesizes that her lab will find the key to how the different cells arise.

So far, the work in our lab has focused on the liver bud around 9.5 days of development, Tremblay says. In the future, we want to study the process later in development but still in the embryo.

By 10.5 days the liver is composed of hepatoblasts in lobes, and a slightly later cells start going down the path toward becoming hepatocytes or cholangiocytes. Thats when well look at the different RNA transcripts, but I think were going to find that the answer has to do more with epigenetics and the different environmental signals the precursors are exposed to. Because developmentally acquired epigenetic traits can be maintained through adulthood, it could provide a mechanism that would explain why some adult liver respond to certain injuries better than others.

Originally posted here:
Embryologist Kim Tremblay Will Explore the Secrets of Liver Regeneration - UMass News and Media Relations

Festive season cheer lets face it, alcohol can lead to the conception of children. It can also damage not only one or two but three generations of your offspring. The revolutionary science of epigenetics informs us that men and women, just like mice, rats, fish, chickens, guinea pigs, dogs, ferrets, pigs and non-human primates, are susceptible to the brain damage known as fetal alcohol spectrum disorder (FASD).

Many couples do not know when they have conceived. If they've been drinking, the risks for the fetus are high. Credit:Greg Newington

Professor Kelly Huffman, of the University of California, is among a number of scientists to establish that exposure to alcohol in utero can not only severely harm the brain and body size of the first baby, but through the epigenetic effect, intellectual impairment, anxiety, depression and motor skill problems can be passed on to grandchildren and great grandchildren.

Over the past 20 years in my post-television work in health and education, I have met large numbers of FASD children, their families and carers. I became an ambassador for the organisation NOFASD because I learnt that most Australians about to have a child have little knowledge of FASD

According to one of Australias leading paediatric specialists on FASD, Heidi Webster of the Sunshine Coast Hospital and Health Service, just two binge-drinking sessions anytime during the first trimester is enough to cause FASD.

Visit link:
If it's to be a merry festive season, consider the child you might conceive - Sydney Morning Herald

Dementia is the common sequelae of age-related Alzheimers disease. This would probably occur due to epigenetic failure. As we know, Alzheimers disease is a progressive disorder that causes brain cells to degenerate. It further disrupts cognitive thinking and impairs the behavioral skills of humans.

The molecular underpinning showed that the condition changes the gene expression in the prefrontal cortex. This is the place in the brain associated with social and cognitive thinking. Researchers tried to reverse the condition by inhibiting the harmful gene transcription. They have conducted studies on mouse models and found that the drugs made to inhibit such activity, would help to restore normal gene function. Also, this will favor the neuronal function at ages.

- Advertisement -

It is a covalent post-translational modification to histone proteins, that is essential for regulating gene expression. It includes methylation, acetylation, phosphorylation, ubiquitylation, and sumoylation. Histone proteins act to package DNA which wraps around the eight histones, into the chromosome. Above all, the nature of packaging determines whether the genes are either upregulated or suppressed.

Scientists identified H3K4me3, a histone modification, elevated in the prefrontal lobe of AD. Precisely, we can say that modification as histone trimethylation at the amino acid lysine 4. This epigenetic change increases the gene transcription, which leads to the production of more histone-modifying enzymes. And so, while targeting those unnecessary enzymes by the selective drugs, we can possibly have an apt treatment for ADs.

Besides, the researchers found some gene targets, which would get affected by epigenetics. One among is Sgk1, where its level is higher in AD patients. Also, it helps in the opening of ion channels and mediates the action of other hormone releases. Interestingly, the methylation of Sgk1 increases the chance of cellular death in other disease manifestations like Parkinsons, amyotrophic lateral sclerosis. In conclusion, we can administer a specific Sgk1 inhibitor to decrease the level of tau protein, and also treat the AD patients.

Do you want to publish on Apple News, Google News, and more?Join our writing community,improve your writing skills, and be read by hundreds of thousands around the world!

- Advertisement -

Source: MedicalXpress

+ Industry Titan Christopher Nolan Balks at Warner Bros. Same-Day Theaters and Streaming Movie Release Schedule+ Archaeologists How do they know where to dig?

+ A new appthe iGenomicsmakes pocket size DNA analyzer possible+ The first wave of vaccination to begin in the UK from today

Read more here:
Epigenetic modifications are the cause of memory loss in Alzheimers disease - News Landed

Obese pregnant women can reduce health-related risks for their unborn child by improving their diet and exercising, researchers have said.

Previous research trials have found high glucose levels in the pregnant mother can trigger changes in the fetus, therefore making the child vulnerable to health conditions in later life.

The most recent study involved more than 550 obese pregnant women. Half of them were asked to improve their diet and start exercising and the other half made no changes to their lifestyle at all.

The researchers looked at DNA patterns among children who were born to mothers who developed gestational diabetes and whether a dietary and physical activity intervention had altered outcomes.

The findings suggested that making lifestyle changes in pregnant did reduce DNA changes in the child which are usually associated with gestational diabetes in the pregnant mother.

Karen Lillycrop, Professor of Epigenetics at the University of Southampton said: These findings suggest that improvements to diet and physical activity can have an impact on the development of their children.

These are very encouraging findings and further studies are now needed to establish whether reducing these epigenetic changes through a healthier lifestyle during pregnancy are accompanied by improved health outcomes for the children in later life.

Professor Lucilla Poston, Tommys Chair of Maternal & Fetal Health and lead investigator of the UPBEAT trial at Kings College London, said: We have known for some time that children of mothers who had gestational diabetes are a greater risk of obesity and poor control of glucose; this new research implies that epigenetic pathways could be involved.

Tommys chief executive Jane Brewin said: Obesity during pregnancy can have lifelong negative impacts on mother and baby so one of the best things mums can do is to improve their health, including their weight, before embarking on a pregnancy.

However, this study shows that mums who are overweight and their babies can still benefit from adopting a healthy diet while pregnant. All mums-to-be need access to healthy eating advice, and those who are overweight should be given non-judgemental practical support and encouragement to eat healthily during pregnancy.

Continue reading here:
Healthy lifestyle in obese mothers can improve the baby's health - Diabetes.co.uk

The Epigenetics Instrument market report will provide one with overall market analysis, statistics, and every minute data relating to the Epigenetics Instrument market necessary for forecasting its revenue, factors propelling & hampering its growth, key market players Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), Bio-Rad (US), and much more. In addition, the key focus points of the report are services, analytics, billings, management, and system.

To get detailed information about the report feel free to contact us @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867#request-sample

Scope: The report offers a statistical analysis of every market aspect that would assist our clients in outlining business strategies and decision-making. Further, it will also aid them to jot down the future interest and accordingly execute their plans.

COVID 19 Impact on Epigenetics Instrument Market: Since the COVID-19 infection flare-up in December 2019, the illness has spread to just about 100 nations around the world with the World Health Organization pronouncing it a general wellbeing crisis. The worldwide effects of the COVID illness 2019 (COVID-19) are as of now beginning to be felt, and will altogether influence the Epigenetics Instrument market in 2020.

Coronavirus can influence the worldwide economy in three primary manners: by straightforwardly influencing creation and request, by making gracefully chain and market interruption, and by its monetary effect on firms and budgetary business sectors.

The episode of COVID-19 has welcomed consequences for some perspectives, similar to flight abrogations; travel boycotts and isolates; cafs shut; all indoor occasions limited; more than forty nations highly sensitive situation pronounced; huge easing back of the flexible chain; financial exchange unpredictability; falling business certainty, developing frenzy among the populace, and vulnerability about future.

Browse Full Report @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867

Details to look for in the report:The Epigenetics Instrument market report entails a market synopsis and offers a definition & outline of the Epigenetics Instrument market. The information provided in the report cover over-the-board data such as market trends, drivers, restraints, opportunities, market shares, challenges, economy, supply chain, and finance in addition to specifics such as software, and communication. Furthermore, the Epigenetics Instrument market is categorized based application(Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other), end-user, technology, the types of product/service(Next-generation Sequencers, qPCR Instruments, Mass Spectrometers, Sonicators, Other), and others, as well as regions North America, Europe, China, Japan, India, Southeast Asia, Other regions (Central & South America, Middle East & Africa, ROW). Additionally, the report encompasses the computed expected CAGR of the Epigenetics Instrument market derived from previous records about the Epigenetics Instrument market and existing market trends together with future developments. The report also highlights other market factors like consumption, asset tracking, and security.

To summarize, the report entails: Overall market summary Growth factors (drivers & restraints) Segmentation Regional analysis Revenue Market players Latest trends and opportunities

Whos at the helm:The team here entails proficient market researchers, knowledgeable consultants, and trustworthy data providers. The team employs proprietary data resources and a number of tools and methods such as NEST, PESTLE, Porters Five Forces, and so on to collect and evaluate the market statistics and other relevant data. Also, the team works round the clock to incessantly update and revise the market data in order to mirror the up-to-the-minute data and trends.

Inquiry to get customization on report @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867#inquiry-for-buying

All in allTo conclude, the Epigenetics Instrument market report will provide the clients with a high-yielding market analysis assisting them to understand the market status and come up with new market avenues to capture hold of the market share.

Read the original:
Research on Epigenetics Instrument Market (impact of COVID-19) 2020-2026: Diagenode (Belgium), Thermo Fisher (US), QIAGEN (Netherlands), Illumina (US)...